Tvardi Therapeutics, Inc. (TVRD)

Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing oral small-molecule therapies that inhibit STAT3, a signaling protein involved in inflammation, fibrosis and cancer. The company's approach is based on the idea that blocking STAT3 activity can address diseases driven by chronic inflammation and fibrotic tissue changes.

Its lead candidate, TTI-101, has been studied in idiopathic pulmonary fibrosis and in hepatocellular carcinoma, and the company has a second compound, TTI-109, designed as a next-generation STAT3 inhibitor. Tvardi's programs grew out of research originally conducted at Baylor College of Medicine.

Tvardi is headquartered in Houston, Texas. It became a Nasdaq-listed company in 2025 through a merger with Cara Therapeutics.